AstraZeneca scade la bursă din cauza unei fuziuni

AstraZeneca is reportedly considering a merger with Bristol-Myers Squibb, which could create the largest pharmaceutical company globally. Investor reactions have led to a significant drop in AstraZeneca's stock. The potential merger, if finalized, would surpass previous pharmaceutical deals in size. Analysts express skepticism about the merger's necessity and feasibility due to overlapping markets and revenue concerns.